Clinical evidence supporting the efficacy of [225Ac]Ac-PSMA RLT in advanced prostate cancer continues to accumulate, particularly in patients who are refractory to [177Lu]Lu-PSMA treatment. This evidence concerns the gene FOLH1 and Familial prostate cancer.